NO327456B1 - Formuleringer inneholdende paracetamol og natriumbikarbonat samt fremgangsmate for fremstilling av slike - Google Patents
Formuleringer inneholdende paracetamol og natriumbikarbonat samt fremgangsmate for fremstilling av slike Download PDFInfo
- Publication number
- NO327456B1 NO327456B1 NO19994294A NO994294A NO327456B1 NO 327456 B1 NO327456 B1 NO 327456B1 NO 19994294 A NO19994294 A NO 19994294A NO 994294 A NO994294 A NO 994294A NO 327456 B1 NO327456 B1 NO 327456B1
- Authority
- NO
- Norway
- Prior art keywords
- paracetamol
- sodium bicarbonate
- formulation
- tablets
- tablet
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims description 90
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 title claims description 90
- 229960005489 paracetamol Drugs 0.000 title claims description 87
- 239000000203 mixture Substances 0.000 title claims description 63
- 238000009472 formulation Methods 0.000 title claims description 53
- 229910000030 sodium bicarbonate Inorganic materials 0.000 title claims description 45
- 235000017557 sodium bicarbonate Nutrition 0.000 title claims description 45
- 238000000034 method Methods 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 4
- 239000000654 additive Substances 0.000 claims description 9
- 239000007916 tablet composition Substances 0.000 claims description 8
- 239000007963 capsule composition Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 6
- 230000009747 swallowing Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 description 48
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 27
- 238000012360 testing method Methods 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 13
- 229910000019 calcium carbonate Inorganic materials 0.000 description 12
- 239000013020 final formulation Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 5
- 229940069428 antacid Drugs 0.000 description 5
- 239000003159 antacid agent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001458 anti-acid effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- -1 colourants Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704524.9A GB9704524D0 (en) | 1997-03-05 | 1997-03-05 | Composition |
| PCT/EP1998/001284 WO1998038983A2 (en) | 1997-03-05 | 1998-02-27 | Swallow tablet comprising paracetamol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO994294D0 NO994294D0 (no) | 1999-09-03 |
| NO994294L NO994294L (no) | 1999-09-03 |
| NO327456B1 true NO327456B1 (no) | 2009-07-06 |
Family
ID=10808717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19994294A NO327456B1 (no) | 1997-03-05 | 1999-09-03 | Formuleringer inneholdende paracetamol og natriumbikarbonat samt fremgangsmate for fremstilling av slike |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6316025B1 (xx) |
| EP (1) | EP0981334B1 (xx) |
| JP (1) | JP2001513801A (xx) |
| KR (1) | KR100465895B1 (xx) |
| CN (1) | CN100389751C (xx) |
| AP (1) | AP1084A (xx) |
| AR (1) | AR011919A1 (xx) |
| AT (1) | ATE240720T1 (xx) |
| AU (1) | AU721851B2 (xx) |
| BG (1) | BG64348B1 (xx) |
| BR (1) | BR9807992A (xx) |
| CA (1) | CA2283408C (xx) |
| CO (1) | CO4940406A1 (xx) |
| CY (1) | CY2367B1 (xx) |
| CZ (1) | CZ294078B6 (xx) |
| DE (1) | DE69814850T2 (xx) |
| DK (1) | DK0981334T3 (xx) |
| EA (1) | EA001918B1 (xx) |
| ES (1) | ES2199435T3 (xx) |
| GB (1) | GB9704524D0 (xx) |
| HK (1) | HK1027026A1 (xx) |
| HU (1) | HU224983B1 (xx) |
| ID (1) | ID22233A (xx) |
| IL (1) | IL131552A (xx) |
| MY (1) | MY119722A (xx) |
| NO (1) | NO327456B1 (xx) |
| NZ (1) | NZ337418A (xx) |
| PE (1) | PE68899A1 (xx) |
| PL (1) | PL190988B1 (xx) |
| PT (1) | PT981334E (xx) |
| SK (1) | SK282277B6 (xx) |
| TR (1) | TR199902175T2 (xx) |
| TW (1) | TW508242B (xx) |
| UA (1) | UA59388C2 (xx) |
| WO (1) | WO1998038983A2 (xx) |
| ZA (1) | ZA981832B (xx) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211246B1 (en) | 1999-06-10 | 2001-04-03 | Mcneil-Ppc, Inc. | Rapidly absorbed liquid compositions |
| NZ508291A (en) * | 1999-11-24 | 2002-09-27 | Mcneil Ppc Inc | Use of acetaminophen in a medicament for treating migraine symptoms |
| GB0006897D0 (en) * | 2000-03-23 | 2000-05-10 | Smithkline Beecham Plc | Medicaments |
| GB0114069D0 (en) * | 2001-06-08 | 2001-08-01 | Smithkline Beecham Plc | Composition |
| GB0129117D0 (en) * | 2001-12-05 | 2002-01-23 | Glaxo Group Ltd | Pharmaceutical composition |
| BRPI0409127A (pt) * | 2003-04-11 | 2006-03-28 | Pfizer | combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio |
| AU2005247048B2 (en) | 2004-05-28 | 2007-12-13 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
| AU2005247047C1 (en) * | 2004-05-28 | 2010-03-11 | Glaxo Group Limited | Oral delivery system |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
| BRPI0520000A2 (pt) * | 2004-10-28 | 2009-04-07 | Novartis Ag | composição compreendendo acetaminofeno, cafeìna e opcionalmente aspirina juntos com um agente alcalino para absorção intensificada |
| WO2006138278A1 (en) * | 2005-06-13 | 2006-12-28 | Paul Rosenberg | Emetic embedded capsule |
| US9060950B2 (en) * | 2005-06-13 | 2015-06-23 | Paul H. Rosenberg, Proximate Concepts, LLC. | Emetic embedded capsule |
| KR100702069B1 (ko) * | 2005-10-31 | 2007-03-30 | (주)이엘티사이언스 | 파라세타몰 경구용 수용산제 복합조성물 및 그 제조방법 |
| CA2629904C (en) | 2005-11-28 | 2018-07-10 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| GB0607085D0 (en) * | 2006-04-07 | 2006-05-17 | Smithkline Beecham Corp | Novel compositions |
| EP2043613A1 (en) * | 2006-07-14 | 2009-04-08 | Fmc Corporation | Solid form |
| US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
| AU2008285244B2 (en) | 2007-08-07 | 2015-02-19 | Stellenbosch University | A medicament |
| KR101687580B1 (ko) | 2016-07-19 | 2016-12-20 | 주식회사 씨.월드 | 의자 등받이부와 프레임부 조립구조 |
| WO2020106735A1 (en) | 2018-11-19 | 2020-05-28 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1182049A (en) * | 1981-07-13 | 1985-02-05 | Francis J. Sterbenz | Apap antacid composition |
| US4942039A (en) * | 1989-05-09 | 1990-07-17 | Miles Inc. | Effervescent analgesic antacid composition having reduced sodium content |
| ES2060736T3 (es) * | 1989-01-12 | 1994-12-01 | Bayer Ag | Composicion antiacida analgesica efervescente con un contenido en sodio reducido. |
| US5348745A (en) * | 1989-05-09 | 1994-09-20 | Miles Inc. | Aqueous granulation solution and a method of tablet granulation |
| CA2021548A1 (en) * | 1989-09-01 | 1991-03-02 | Ronald Nash Duvall | Effervescent cold or sinus allergy medicine composition having reduced sodium content |
| DE19502789A1 (de) | 1995-01-28 | 1996-08-01 | Dirk Krischenowski | Arzneimittel |
-
1997
- 1997-03-05 GB GBGB9704524.9A patent/GB9704524D0/en active Pending
-
1998
- 1998-02-27 US US09/380,453 patent/US6316025B1/en not_active Expired - Lifetime
- 1998-02-27 SK SK1197-99A patent/SK282277B6/sk not_active IP Right Cessation
- 1998-02-27 EA EA199900709A patent/EA001918B1/ru not_active IP Right Cessation
- 1998-02-27 HU HU0001501A patent/HU224983B1/hu unknown
- 1998-02-27 ID IDW990954A patent/ID22233A/id unknown
- 1998-02-27 AP APAP/P/1999/001638A patent/AP1084A/en active
- 1998-02-27 UA UA99094955A patent/UA59388C2/uk unknown
- 1998-02-27 JP JP53816998A patent/JP2001513801A/ja active Pending
- 1998-02-27 TR TR1999/02175T patent/TR199902175T2/xx unknown
- 1998-02-27 NZ NZ337418A patent/NZ337418A/xx not_active IP Right Cessation
- 1998-02-27 PL PL335502A patent/PL190988B1/pl unknown
- 1998-02-27 ES ES98913664T patent/ES2199435T3/es not_active Expired - Lifetime
- 1998-02-27 IL IL13155298A patent/IL131552A/en not_active IP Right Cessation
- 1998-02-27 DK DK98913664T patent/DK0981334T3/da active
- 1998-02-27 AT AT98913664T patent/ATE240720T1/de active
- 1998-02-27 WO PCT/EP1998/001284 patent/WO1998038983A2/en active IP Right Grant
- 1998-02-27 CA CA002283408A patent/CA2283408C/en not_active Expired - Lifetime
- 1998-02-27 DE DE69814850T patent/DE69814850T2/de not_active Expired - Lifetime
- 1998-02-27 CN CNB988045508A patent/CN100389751C/zh not_active Expired - Lifetime
- 1998-02-27 CZ CZ19993148A patent/CZ294078B6/cs not_active IP Right Cessation
- 1998-02-27 AU AU68282/98A patent/AU721851B2/en not_active Expired
- 1998-02-27 PT PT98913664T patent/PT981334E/pt unknown
- 1998-02-27 BR BR9807992-1A patent/BR9807992A/pt not_active Application Discontinuation
- 1998-02-27 EP EP98913664A patent/EP0981334B1/en not_active Expired - Lifetime
- 1998-02-27 KR KR10-1999-7007976A patent/KR100465895B1/ko not_active IP Right Cessation
- 1998-03-03 AR ARP980100938A patent/AR011919A1/es active IP Right Grant
- 1998-03-03 MY MYPI98000911A patent/MY119722A/en unknown
- 1998-03-03 CO CO98011455A patent/CO4940406A1/es unknown
- 1998-03-03 PE PE1998000148A patent/PE68899A1/es not_active IP Right Cessation
- 1998-03-04 ZA ZA981832A patent/ZA981832B/xx unknown
- 1998-03-05 TW TW087103218A patent/TW508242B/zh not_active IP Right Cessation
-
1999
- 1999-09-03 NO NO19994294A patent/NO327456B1/no not_active IP Right Cessation
- 1999-09-03 BG BG103714A patent/BG64348B1/bg unknown
-
2000
- 2000-08-30 HK HK00105436A patent/HK1027026A1/xx not_active IP Right Cessation
-
2003
- 2003-07-15 CY CY0300050A patent/CY2367B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327456B1 (no) | Formuleringer inneholdende paracetamol og natriumbikarbonat samt fremgangsmate for fremstilling av slike | |
| AU2001260212C1 (en) | Composition | |
| NO330270B1 (no) | Umiddelbart opplosende farmasoytisk doseform og fremgangsmate for a danne granuler | |
| KR20080096851A (ko) | 에제티미베 조성물 | |
| EP0749308B1 (en) | Film coated tablet of paracetamol and domperidone | |
| AU2001260212A1 (en) | Composition | |
| RU2262922C2 (ru) | Способ прессования для получения лекарственной формы фенитоина натрия | |
| US9592197B2 (en) | Dosage form containing diphenhydramine and another drug | |
| JP6476331B2 (ja) | イソニアジドの顆粒およびリファペンチンの顆粒を含む分散性錠剤の形態の抗結核性の安定な医薬組成物ならびにその製造方法 | |
| NO822385L (no) | Terapeutisk preparat. | |
| EP0975337B1 (en) | Fast release compressed tablet of flurbiprofen | |
| JP2002512614A (ja) | 化学的かつ熱的に安定なノルアステミゾール製剤 | |
| RU2174836C1 (ru) | Фармацевтическая композиция, обладающая анальгезирующим действием | |
| EP3398590A1 (de) | Schmelztablette, enthaltend ein h1-antihistaminika | |
| JPH02282322A (ja) | 有効物質の浸食制御による放出システムおよびその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTME, IE |
|
| MK1K | Patent expired |